Metagenomi

This week in San Diego we were pleased to present our progress on two separate occasions - at ASH, where we shared our latest preclinical data in hemophilia A; and at Nature's "RNA at the bench and bedside IV," where we presented our highly specific and efficient genome editing tools. To learn more, see our latest press releases for updates from ASH and the Nature Conference "RNA at the bench and bedside IV." ASH: https://lnkd.in/g44m7gQn Nature Conference: https://lnkd.in/g53gCsfZ

Today, Metagenomi presented a novel compact base editing system, small enough to fit within the packaging limits of standard AAVs. These systems hold potential to broaden the therapeutic applications of genetic medicine, particularly in targeting neuromuscular disorders. Take a look at our poster titled “Engineering of compact and efficient adenine base editors from metagenomic derived systems” presented at the American Institute of Chemical Engineers (AIChE) 7th International Conference on CRISPR Technologies in San Diego, CA. Poster: https://lnkd.in/gmJZMrTP Press Release: https://lnkd.in/gGKRXjT6

Meeting on the Mesa attendees - Be sure to add our company presentation on Tuesday, October 8th, to your schedule! Join Metagenomi President & COO, Jian Irish, as she provides a company overview and highlights our latest innovations. #MeetingOnTheMesa Alliance for Regenerative Medicine

Metagenomi has announced that company management will participate in both a fireside chat and panel discussion at Chardan's 8th Annual Genetic Medicines Conference. For further details, please refer to the press release here: https://lnkd.in/gp78uNRZ

Metagenomi is excited to announce preclinical data for our lead program in hemophilia A, demonstrating durable factor VIII (FVIII) activity levels through twelve months of follow up. Hemophilia A is the most common X-linked inherited bleeding disorder, caused by a large variety of mutations in the FVIII gene leading to a loss of functional FVIII protein. Our goal is to provide a one-time, curative treatment for adults and children with hemophilia A. For further information, be sure to read the full press release linked below. Additionally, Metagenomi management will be holding a conference call tomorrow, September 4th at 8:30am EST. For login information, please visit Metagenomi's investor page on the Company website. Press Release: https://lnkd.in/g3XAnmgQ

We are excited to announce Metagenomi's poster presentation at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference, highlighting our AI-enabled SMART editing platform. While there is no shortage of naturally occurring proteins that we can discover using our metagenomics platform, AI is one of several approaches we leverage to generate novel systems capable of highly efficient in vivo gene editing. Read our latest press release here for more: https://lnkd.in/gPbVgGTE

Metagenomi is looking forward to presenting at the upcoming Wells Fargo and HC Wainwright investor conferences. For further details, please refer to the press release here: https://lnkd.in/gum7K-pv

Today we announced business updates along with our Q2 financial results. You can find the key highlights below, with the full details available in the press release here: https://lnkd.in/gPq3VE6t

Today we announced Metagenomi's data presentations at recent scientific conferences and first quarter 2024 financial results. See the press release here: https://lnkd.in/gwAkW9z3

Metagenomi is looking forward to sharing scientific updates at the American Society of Gene and Cell Therapy’s 27th Annual Meeting in Baltimore, MD. Be sure to stop by our poster sessions to connect with our scientists and learn more.